| Status: Not endorsed (Statement of Advice) | |
Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). |
|
Medicine details |
|
| Medicine name | glycopyrronium / formoterol fumurate dihydrate (Bevespi Aerosphere®) |
| Formulation | suspension for inhalation |
| Reference number | 1189 |
| Indication | As maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD) |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Respiratory system |
| Assessment type | N/A |
| Status | Not endorsed (Statement of Advice) |
| Date of issue | 13/02/2019 |
| Further information Exclusion criteria 6 applies: product is a new formulation of an established medicine |
|